An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: Clipped β2-glycoprotein-I

Annals of Surgical Oncology

Volumn 13, Issue 9, 2006, Pages 1241-1251

  Beecken, Wolf Dietrich C ^a   Engl, Tobias ^a   Ringel, Eva M ^a   Camphausen, Kevin ^b   Michaelis, Martin ^a   Jonas, Dietger ^a   Folkman, Judah ^c   Shing, Yuen ^c   Blaheta, Roman A ^a,d  

^a GOETHE UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

2 glycoprotein I; Angiogenesis; Transitional cell carcinoma; Tumor dormancy

Indexed keywords

BETA2 GLYCOPROTEIN 1; CELL SURFACE RECEPTOR; LIPOCORTIN 2; PLASMA PROTEIN; PLASMIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CELL FRACTIONATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INVASIVE CARCINOMA; MASS SPECTROMETRY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN ISOLATION; PROTEIN SECRETION; SCID MOUSE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANNEXIN A2; BETA 2-GLYCOPROTEIN I; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; MASS SPECTROMETRY; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PLASMIN; UMBILICAL VEINS; URINARY BLADDER NEOPLASMS;

EID: 33748958117     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9009-9     Document Type: Article

References (49)

1. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG, Cote RJ. Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 1998; 160:645-59.
2. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur Urol 2002; :41105-112.
3. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3:643-51.
4. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses MA, Lane WS, Cao Y, Sage BH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-28.
5. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285:1926-28.
6. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-53.
7. Beecken W-D, Fernandez A, Joussen AM, Achilles E-G, Flynn E, Lo K-M, Gillies SD, Javaherian K, Folkman J, Shing Y. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 2001; 93:382-87.
8. Beecken W-D, Fernandez A, Panigrahy D, Achilles E-G, Kisker O, Flynn E, Joussen AM, Folkman J, Shing Y. Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology 2000; 56:521-26.
9. Day JR, O'Hara PJ, Grant FJ, Lofton-Day C, Berkaw MN, Werner P, Arnaud P. Molecular cloning and sequence analysis of the cDNA encoding human apolipoproteinH (β2-Glyko-protein-1). Int J Clin Lab Res 1992; 21:256-63.
10. Schultze HE, Heide K, Haupt H. über ein bisher unbekanntes niedermolekulares β2-Globulin des Humanserums. Naturwissenschaften 1961; 148:719.
11. Shi T, Iverson GM, Qi JC, Cockerill KA, Linnik MD, Konecny P, Krilis S. β2-Glykoprotein-1 binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped β2-glykoprotein-1. Proc Natl Acad Sci USA 2004; 101:3939-943.
12. Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis SA. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157:744-51.
13. Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H. Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998; 91:4173-79.
14. Horbach DA, van Oort ET, Lisman T, Maijers JC, Derksen RH, de Groot PG. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemostasis 1999; 81:87-95.
15. Itoh Y, Inuzuka K, Kohno I, Wada H, Shiku H, Ohkura N, Kato H. Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem (Tokyo) 2000; 128:1017-24.
16. Nakaya Y, Schaefer EJ, Brewer HB Jr. Activation of human post heparin lipoprotein lipase by apolipoprotein H (beta 2-glycoprotein I). Biochem Biophys Res Commun 1980; 95:1168-72.
17. Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by beta 2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemostasis 1993; 70:342-5.
18. Nimpf J, Bevers EM, Bomans PH, Till U, Wurm H, Kostner GM, Zwaal RF. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta 1986; 884:142-149.
19. Nimpf J, Wurm H, Kostner GM. Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63:109-14.
20. Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, Balestrieri G, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41:215-23.
21. McNeil HP, Simpson RJ, Chersterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4.
22. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335:1544-7.
23. Shevchenko A, Chernushevich I, Wilm M, Mann M. De Novo peptide sequencing by nanoelectrospray tandem mass spectrometry using triple quadrupole and quadrupole/time-of-flight instruments. Methods Mol Biol 2000; 146:1-16.
24. Guerin J, Sheng Y, Reddel S, Iverson GM, Chapman MG, Krilis SA. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 2002; 277:2644-9.
25. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H, Cinatl J Jr. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004; 65:520-7.
26. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275:1521-4.
27. Wurm H. beta 2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16:511-5.
28. Polz E, Kostner GM. Binding of beta 2-glycoprotein-I to intralipid: determination of the dissociation constant. Biochem Biophys Res Commun 1979; 90:1305-12.
29. Ma K, Simantow R, Zhang J-C, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of β2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275:15541-48.
30. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005; 105:1964-69.
31. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
32. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2:689-92.
33. Rübben H, Otto T. Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom. Aktuelle Aspekte in der Therapie. Urologe (A) 2001; 40:464-67.
34. Westphal JR, Van't Hullenaar R, Geurts-Moespot A, Sweep FC, Verheijen JH, Bussemakers MM, Askaa J, Clemmensen I, Eggermont AA, Ruiter DJ, De Waal RM. Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 2000; 86:760-67.
35. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998; 58:1298-304.
36. Cai G, Satoh T, Hoshi H. Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum. Biochim Biophys Acta 1995; 1269:13-8.
37. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, Valesini G. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in antiphospholipid syndrome-related tissue damage. Clin Exp Immunol 1999; 115:214-9.
38. Knudsen BS, Silverstein RL, Leung LL, Harpel PC, Nachman RL. Binding of plasminogen to extracellular matrix. J Biol Chem 1986; 261:10765-71.
39. Li Z, Krilis SA. Anti-beta(2)-glycoprotein I antibodies and the antiphospholipid syndrome. Autoimmun Rev 2003; 2:229-34.
40. Wu HL, Chang BI, Wu DH, Chang LC, Gong CC, Lou KL, Shi GY. Interaction of plasminogen and fibrin in plasminogen activation. J Biol Chem 1990; 265:19658-64.
41. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol 2001; 106:33-42.
42. Tsihlias J, Grossman HB. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am 2000; 27:39-46.
43. Morgan RO, Fernandez MP. Annexin gene structures molecular evolutionary genetics. Cell Mol Life Sci 1997; 53:508-15.
44. Evans TC, Nelsestuen GL. Calcium and membrane-binding properties of monomeric and multimeric annexin II. Biochemistry 1994; 33:13231-38.
45. Emans N, Gorvel JP, Walter C, Gerke V, Kellner R, Griffiths G, Gruenberg J. Annexin II is a major component of fusogenic endosomal vesicles. J Cell Biol 1993; 120:1357-69.
46. Creutz CE. The annexins and exocytosis. Science 1992; 258:924-31.
47. Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-c. J Cell Biol 1994; 126:539-48.
48. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator I. Identity with annexin II. J Biol Chem 1994; 269:21191-97.
49. Tokes AM, Hortovanyi E, Kulka J, Jackel M, Kerenyi T, Kadar A. Tenascin expression and angiogenesis in breast cancers. Pathol Res Pract 1999; 195:821-28.